|
Management of other conditions, including cancer. The assessment of pain in older patients may require a more comprehensive assessment than in younger patients; the assessment needs to include conditions that may be exacerbated by or may exacerbate or in some way modulate the perception of pain, such as depression, disability, and comorbidities. Simultaneous management of these conditions may enhance the effectiveness of pain management. Other conditions, such as functional dependence, may be followed to monitor the effectiveness of pain treatment. Self-report of pain by older individuals is reliable, even in the presence of moderate dementia. Vertical visual scales, such as pain thermometers, and numerical or verbal descriptor scales are the most suitable for older individuals with cognitive impairment and or a low educational level. Observation of pain behavior is useful and reliable in assessing pain in individuals unable to verbalize their complaints. Nonpharmacological treatment may be helpful in selected individuals. Special attention should be paid to whether the pain is constant or enhanced by certain movements. In the latter case, the administration of analgesics could be timed or limited to the time of pain-producing activities. In the absence of risk of gastrointestinal bleeding recent bleeding, history of H pylori gastritis, thrombocytopenia, or anticoagulation ; , COX-1 inhibitors are more cost-effective than COX-2 inhibitors, as long as indomethacin, piroxicam, mefenamic acid, and ketorolac are avoided. Of the COX-2 inhibitors, rofecoxib has a lesser risk of drug interactions. Older individuals may have an increased sensitivity to opioids, due to decreased hepatic metabolism and decreased renal excretion, as well as a reduced number of opioid receptors due to brain atrophy. Morphine, hydromorphone, oxycodone, and fentanyl are the opioids most commonly used. In general, one should initiate treatment with lower doses and longer dose intervals than would be used in younger patients. Dose escalations should be guided by individual pain relief, just as they are for younger subjects. Drinking 4 ounces of red wine daily can raise your good cholesterol, according to Michael Bond, D.O., family physician on the medical staff at Presbyterian Hospital of Plano. Consuming 25 grams of soy protein daily can reduce your risk of heart disease and breast cancer and lower your bad cholesterol, according to the U.S. Food and Drug Administration. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease, because indomethacin prostaglandin.
| Roses for same day delivery will of necessity continue to be difficult to guarantee for worldwide delivery for some time to come among most companies. 300mg 100 pills ; 600mg 100 pills ; 200mg 100 pills ; 25mg 100 pills ; 1mg 120mg 100 pills ; 28 day 3 month 21 day 3 month - Sale! Choose 21 day and save! 60 pills 10mg mL 1% 2mL x 10 30mg mL 3% 2mL x 10 2% 5ml ; 500mg 100 tablets ; 500mg 100 capsules ; 1 gram 100 tablets ; 37.5 325mg 60 pills ; 50mg 90 pills ; Generic 50mg 30 pills ; Generic 50mg 100 pills ; 1% 25 ml ; 15g Plain Cream 15g Cream w Sunblock 15g Gel w Sunblock Generic 4% Hydroquinone Cream 30g x 3 Generic 2% Hydroquinone Cream 30g x 3 0.05% 50 grams ; 0.05% 50 grams ; 400mg 50 pills ; 600mg 50 pills ; 7.5mg 90 pills ; 15mg 90 pills ; Generic 7.5mg 100 pills ; Generic 15mg 100 pills ; 90 pills 10meq 90 pills ; 10mg 100 pills ; 250mg 100 pills and ismo. Indomethacin cephalexin etc protonix creates the need for biaxin.
|
1. MAKE AN APPOINTMENT--AND KEEP IT--WITH A HEALTH CARE PROVIDER WHO HAS EXPERIENCE TREATING HCV and imdur.
Conclusion, intraperitoneal injection of pentobarbital caused significant nociception which was lowered by adding lidocaine to the formulation, although still significantly higher that the control level. Further studies are needed with the aim of optimising the lidocaine concentration and examine the effect of the combination of lidocaine and a long acting local anaesthetic agent, e.g. bupivacaine. D.2 LAMOTRIGINE PLASMA CONCENTRATIONS ARE REDUCED BY THE ORAL CONTRACEPTIVE PILL - RESULTS FROM A DOUBLE BLIND, PLACEBO CONTROLLED TRIAL IN PATIENTS WITH EPILEPSY J. Christensen, V. Petrenaite, P. Sidenius, I. hman, T. Tomson, and A. Sabers Departments of Clinical Pharmacology and Neurology, Aarhus University Hospital, 8000 Aarhus C, Denmark The study evaluates the effect of oral contraceptives on lamotrigine plasma concentrations. Women with epilepsy, treated with lamotrigine in monotherapy and taking combination type oral contraceptives, were randomized to treatment with placebo or a standard contraceptive pill in a crossover fashion. The dose corrected trough concentration of lamotrigine following 21 days of placebo treatment was compared to the concentration after 21 days of treatment with the oral contraceptive pill. The change of lamotrigine concentration in the seven days pause following oral contraceptives was also analyzed. The mean lamorigine concentration placebo versus oral contraceptives ; was 187% 95% CI: 141% 232% ; . There was a significant increase in lamotrigine concentration in the two treatment pauses following oral contraceptives 175% 95% CI: 146% 203% ; and 173% 95% CI: 121% 225% ; respectively ; . For patients allocated to oral contraceptives, the concentration of lamotrigine fell to the baseline value after one week of treatment, whereas for patients allocated to placebo, the lamotrigine concentration remained elevated. Oral contraceptives significantly decrease the concentration of lamotrigine. The change in lamotrgine concentrations was observed within one week, indicating that induction and deinduction of UGT pathways may be faster than what is seen for other metabolic pathways. Further studies of the clinical significance of these findings are warranted. D.3 PGE2 CAUSES ENDOTHELIUM-DEPENDENT VASODILATION BY BINDING TO THE EP4-RECEPTOR AND STIMULATING NO-SYNTHESIS IN MOUSE AORTA A. Hristovska, L.E. Rasmussen, P.B.L. Hansen, O. Skott, B.L. Jensen Prostaglandin E2 PGE2 ; acts as a physiologically important vasodilator in numerous vascular beds by binding to four E-prostanoid receptors, designated EP1, EP2, EP3 and EP4. The pathways by which PGE2 causes vasodilatation was investigated by mounting the mouse aorta in a wire myograph. Experiments were conducted in the presence of the irreversible COX-inhibitor indomethacin 5x10-6 M ; . PGE2 concentration dependently constricted mouse aorta EC50 1, 5x10-5M ; and further constricted phenylephrine- EC90 ; preconstricted aorta EC50 8x10-7M ; . PGF2 also constricted the aortic rings in a concentration-dependent manner EC50 10-5M ; . PGE2 caused no further constriction of PGF2preconstricted aortic rings. Blockade of TP-receptors with S18886 10-7 M ; inhibited PGE2-and PGF2 -induced contraction. In the presence of S18886 10-7 M ; , PGE2 relaxed PE-preconstricted aortic rings IC50 5x10-8 M ; , when added in single concentrations. The PGE2 mediated vasorelaxation was dependent on endothelial NO-formation, since removal of the endothelium as well as blockade of the NOS-synthase with L-NAME 10-4 M ; abolished the relaxation. In aortas from eNOS mice, PGE2 did not mediate a relaxation. The selective EP4-receptor blocker ONO-AE3-208 10-8 M ; also abolished the PGE2mediated relaxation and the relaxation was absent in aortas from EP4 mice. The current data indicate that PGE2 has simultaneous and divergent effect on blood vessels: at high.
13; highest risk: flurbiprofen ansaid ; , piroxicam feldene ; , fenoprofen, indomethacin indocin ; , meclofenamate meclomen ; , and oxaprozin and sorbitrate.
Indapamidum inderal indiaral indinavir indinavira indinavirum indocid indocin indoflam indometacina indomethacin indomethacinum indovar induken inegy inflaced influenzol inh inhibitron inipomp innovace innozide inoflox insegar all 'i' meds.
Introduction: In NDI due to mutations of the V2 vasopressin receptor, indomethacin Indo ; + thiazide TZ ; treatment induces a modest reduction in urine volume V ; . Here, we tested whether furosemide FU ; , which inhibits urinary dilution in the thick ascending limbs of Henle's loops could also reduce V and increase urine osmolality Uosm in mosm kg H2O and imipramine.
Figure A shows total admissions and male and female admissions for poisoning each month. There has been a general decrease in numbers across the board probably corresponding, inversely, to the increase in number of medical patients seen in the Poisons Ward. The number of medical admissions to the poisons ward has more than trebled since 2002, for example, drug indomethacin.
29. Mikkelean E J, Rapoport J L, Nee L, Grumau C, Mendelson W, Gillin J C, "Childhood enuresis 1: sleep patterns and psychopathology", Arch. Gen. Psych. 1980 37: pp. 1, 1391, 144. Norgaard J P, Djurhaus J C, "The pathophysiology of enuresis in children in children and young adults", Clin. Paediat. 1993 7: pp. 59. 31. Norgaard J P, "Pathophysiology of nocturnal enuresis", Scand. J. Urol. Nephrol. 1991 140: pp. 135 suppl ; . 32. Brooks L J, Topol H I, "Enuresis in children with sleep apnoea", J. Paedr. 2003 142: pp. 515518. 33. Neveus T, "The role of sleep and arousal in nocturnal enuresis", Acta. Paediatr. 2000 3: pp. 294302. 34. Wolfish N, "Sleep arousal function in enuretic males", Scand. J. Urol. Nephrol. 1999 202: pp. 2426 suppl ; . 35. Hjalmas K, Arnold T, Bower W, Caine P et al., "Nocturnal enuresis an international evidence based management strategy", J. Urol. 2004 171: pp. 2, 5452, 561. Butler R J, Robinson J C, Holland P, boherty-Williams D, "Investigating the three systems approach to complex childhood nocturnal enuresis- Medical treatment intervention", Scand. J. Urol. Nephrol. 2004 38: pp. 117121. 37. Devlin J B, O'Cathain C, "Predicting treatment outcome in nocturnal enuresis", Arch. Dis. Child 1990 65: pp. 118162. 38. Glazner C M, Evans J H, Peto R E, "Alarm interventions for nocturnal enuresis in children", Cochrane Database Sys. Rev. 2003 ; : CD002911. 39. Wailins A, "Increased urinary nitrite excretion in primary enuresis: effects of indomethacin treatment on urinary and serum osmolality and electrolytes, urinary volumes and nitrite excretion", BJU Int. 2002 90: pp. 294301. 40. van Londen A, Van Londen-Barenstem M W, Van Son M J, Mulder G A, "Arousal training for children suffering from nocturnal enuresis: a 2 1 year follow-up", Beh. Res. Ther. 1993 31: pp. 613615. 41. Asrin N H, Sneed T J, Foxx R M, "Dry-bed training: rapid elimination of childhood enuresis", Beh. Res. Ther. 1974 12: pp. 146147. 42. Glazener C M, Evans J H, "Simple behavioral and physical intervention for nocturnal enuresis in children", Cochrane Database Syst. Rev. 2004 ; : CD003637 43. Glazener C M, Evans J H, Peto R E, "Complex behavioral and educational interventions for nocturnal enuresis in children", Cochrane Database Syst. Rev. 2004 CD004668 44. Penesi M, Pitter M, Bordugo A et al., "Behavioural therapy for primay nocturnal enuresis", J. Urol. 2004 171: pp. 408410. 45. Fjelestad-Paulsen A, Laborde K, Kinderman C, Czemichow P, "Water balance hormones during long term follow-up of oral DDAVP treatment in diabetes insipidus", Acta Paediatrica 1993 82: pp. 752757. 46. Harris A S, Nilsson I M, Wagner Z G, Alkner U, "Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin", J. Pharma. Sci. 1986 75: pp. 1, 0851, 088. Harris A S, Ohlin M, Lethagen S, Nilsson I M, "Effects of concentration and volume on nasal bioavailability and biological response to desmopressin", J. Pharma. Sci. 1988 77: pp. 337339. 48. Williford S L, Bernstein S A, "Intranasal desmopressin induced hyponatraemia", Pharmacotherapy 1996 16: pp. 6674. 49. Berstein S A, Williford S L, "Intranasal desmopressin-associated hyponatraemia: a case report and literature review", J. Fam. Pract. 1997 44: pp. 203208. 50. Odeh M, Oliven A, "Coma and seizures due to severe hyponatraemia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis", J. Clin. Pharma. 2001 41: pp. 582584. 51. Apakama D C, Bleetman A, "Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis", J. Accid. Emerg. Med. 1999 16: pp. 229230. 52. Schwab M, Ruder H, "Hypernatraemia and cerebral convulsion due to DDAVP administration in patients with enuresis nocturna or urine concentration testing", Eur. J. Pediatr. 1997 156: p. 668. 53. Robson W L, Norgaard J P, Leung A K, "Hyponatraemia in patients with nocturnal enuresis treated with DDAVP", Eur. J. Paediat. 1996 155: pp. 959962. 54. Nijman J M, "Paediatric voiding dysfunction and enuresis", Curr. Opin. Urol. 2000 10: pp. 365370. 55. Tahmaz L, Kihar Y, Yikliri I et al., "Combination therapy of mipramine and oxybutynin in children with enuresis nocturna", Urol. Int. 2000 65: pp. 135139. 56. Kosar A, Arikan N, Dincel C, "Effectiveness of oxybutynin hydrochloride in the treatment of enuresis nocturna a clinical and Urodynamic study", Scand. J. Urol. Nephrol. 1999 3: pp. 115118. 57. Bradbury M G, Meadow S R, "Combined treatment of enuresis alarm and desmopressin for nocturnal enuresis", Acta. Paediatrica 1995 84: pp. 1, 0141, 018. Leebeek-Groenewegen A, Bkom J, Suthai R et al., "Efficacy of desmopressin combined with alarm therapy for monosymptomatic nocturnal enuresis", J. Urol. 2001 166: pp. 2, 4562, 458. Martin M R, Schiff A A, "Fluphenazine nortriptyline in the irritative bladder syndrome: a double-blind placebo-controlled study", Br. J. Urol. 1984 56: p. 178. 60. Lose G, Jorgensen L, Thunedborg P, "Doxepin in the treatment of female detrusor overactivity. A randomized double-blind crossover study", J. Urol. 1989 142: p. 1, 024 and tofranil.
Omega 3 in food omega 3 fish oil - omega 3 supplements - omega 3 foods pure certified hoodia 1000mg certified hoodia diet pills, for example, indomethacin ductus.
Celecoxib and L-NAME Panel D. Blood pressure elevations following indomethacin and L-NAME administration. 10-12 week old male C57BL 6 mice were administered L-NAME and or indomethacin. Systolic blood pressure was monitored daily. , control mice; , L-NAME; , indo and indapamide.
Is a lack of consistent change in in these reports due to variations fat, species, and tissues assayed. the rehabilitating effect of vitamin E on fatty acid composition has not been reported. Previous studies from this laboratory of skeletal muscle from E-deficient rabbits indicated that muscle fiber diameter 25 ; , ultrastructural damages 26 ; , and mitochondrial respiration rate 27 ; recovered after 30 days of vitamin E therapy to young vitamin E-deficient rabbits. The present study attempts to elucidate the effect of vitamin E depletion and repletion on the fatty acid composition of rabbit tissues using one dietary fat level with vitamin E and indomethacin a prostaglandin synthetase inhibitor ; as variables. The substrate for prostaglandin biosynthesis is arachidonic acid 20-4 w6 ; . Machlin et al. 23 ; have reported that aspirin, a prostaglandin synthetase inhibitor, was able to prevent some symptoms of vitamin E deficiency and that prostaglandin synthesis is greatly enhanced in vitamin Edeficient rat sera 24 ; . In the present study blood creatine phosphokinase CPK ; was used as an indicator of the degree of muscle atrophy in the rabbit. Elevation of CPK has been reported in both genetic and nutritional muscular dystrophy 33-35 ; . Materials.
Jp background and aim: we recently reported that cyclooxygenase cox ; -2 is upregulated in the rat small intestine after administration of indomethacin, and this may be the key to non-steroidal anti-inflammatory drug nsaid ; -induced intestinal damage and lozol.
Indomethacin poses a higher risk than many others for this adverse effect.
Gistic combination of the drugs and the NSAIDs. As MRP overexpression in those MDR cell lines has been well characterised [35, 36], the expression of MRP in all the cell lines utilised in this report was compared. The expression of MRP was observed in cell lysates from A549, in agreement with a recent publication [37], but not in equivalent preparations from DLKP when examined by immunoblot Figure 3 ; . However, in plasma membrane vesicle preparations from DLKP, expression of MRP was observed Figure 3 ; . There have been no previous studies on MRP expression in DLKP. Associated RTPCR studies indicated that mRNA for MRP was present in both the DLKP and A549 cell lines Figure 4 ; . LTC4 transport into inverted vesicles from HL60 ADR and DLKP To determine if the NSAIDs were acting directly on the MRP pump, the uptake of [3H]-LTC4, a glutathioneconjugate which is very eYciently transported by MRP, into inside-out plasma membrane vesicles prepared from the MRP-overexpressing HL60 ADR cell line or from the DLKP cell line, was examined using a rapid ltration procedure [28]. HL60, the parental line from which HL60 ADR was derived, has been demonstrated to possess relatively low rates of LTC4 transporting ability [38]. The HL60 ADR vesicles provide a relatively pure preparation of functional MRP for performing direct inhibition studies. These data suggest that the positive NSAIDs, especially sulindac and indomethacin, have MRP pump inhibitory activity, whereas inactive NSAIDs, naproxen and piroxicam, do not Table 5 ; . Glutathione-S-transferase assays MRP can act as an eZux pump for glutathione conjugates and it has been suggested that glutathione metabolism is an important factor in drug eZux from MRP-overexpressing cell lines [39]. As indomethacin is known to be an inhibitor of glutathione-S-transferases [40, 41], we tested the other NSAIDs in a total glutathione-S-transferase assay [29], using a DLKP cell extract and the results are shown in Table 6. The most inhibitory NSAID in the assay was piroxicam, which was negative in the combination assays, followed by those NSAIDs that were positive for a synergistic eVect. These data suggest that the NSAIDs do possess glutathione and isoflavone and indomethacin.
Minor ailments. They discovered that the proportion of physcian consultations for these conditions tended to increase as household income, education, and occupational rank increased.119 Hetherington and Hopkins reported that people with low income are significantly more "symptom-insensitive" than those of high income.120 Previous experience likely plays a key role in attitudes and behaviours involving minor illnesses. Several studies have focused on the relationships between prior experience and illness behaviours for a given symptom. Safer et al reported that patients with familiar or frequently experienced symptoms 11 days ; took a much longer time than did patients with new symptoms 3 days ; to make decisions.122 In Banks and Keller's study, 239 families were randomly selected and then a member of the family usually the mother ; was interviewed. For a list of symptoms, subjects were asked if anyone in the family had displayed such symptoms. They were questioned on what choice of treatment they would make, without considering their previous experience. Those who had previous symptom experience, though, expressed less anxiety or concern than those to whom the illnesses were new.35 It is not surprising that people may have different responses when they suffer different kinds of conditions. Many researchers are interested in understanding reactions to common symptoms of minor illness. Verbrugge and Ascione analyzed the incidence of symptoms related to respiratory and musculoskeletal illnesses to see how people cared for them. For mainly acute ; respiratory symptoms, OTC drugs were chosen more often than prescription medicines. But for musculoskeletal symptoms chronic ; , prescription medicines became more important than OTC choices. Furthermore, persons with respiratory symptoms used less formal medical care than did those with musculoskeletal symptoms.123 Thus, according to Verbrugge and Ascione's findings, 22.
SUPPLY AND STORAGE: Tablets: 2 mg; store at room temperature 15-30C ; .1 Keep dry and protect from light. Injection: 60 mg ampoule single use each mL contains 6 mg busulfan. Also contains dimethylacetamide and polyethylene glycol. Keep refrigerated between 2-8C.2 SOLUTION PREPARATION AND COMPATIBILITY and isoniazid.
Table 1. Carreira's ephedrine mediated alkynylation.17.
LizcanoGil LA, Garcia-Cruz D, Sanchez-Corona J. bifida OEIS ; complex in a male prenatally exposed to diazepam. Arch Med Res 1995; 26: 95-96. Llanas B, Cavert MH, Apere H, Demarquez JL. Les effets secondaires du ktoprofne aprs exposition intra-utrine. Intrt du dosage plasmatique. Arch Pediatr 1996; 3: 248-253. Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 551-63. Locatelli A, Vergani P, Bellini P, et al. Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG 2001; 108: 325-326. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42: 1336-1339. Loebstein R, Lalkin A, Addis A, et al. Pregnancy outcome after gestational exposure to terfenadine: a multicenter, prospective controlled study. J Allergy Clin Immunol 1999; 104: 953-956. Loffredo CA, Ferencz C, Rubin JD, et al. A comparative epidemiologic evaluation of risk factors for hypoplastic left heart syndrome, aortic stenosis, and coarctation of the aorta. Teratology 1996; 53: 115. Loffredo LC, de Souza JM, Yunes J, et al. Cleft lip and palate: casecontrol study. Rev Saude Publica 1994; 28: 213-217. Lojodice G, Vento R, Dececco C. Female pseudohermaphroditism probably induced by a progestinic administered intramuscularly: 17alpha-hydroxyprogesterone capronate. Minerva Pediatr 1964; 16: 946950. Loke KH, Salleh R. Electroconvulsive therapy for the acutely psycotic pregnant patient: a review of 3 cases. Med J Malaysia 1983; 38: 131-133. Long WA, Willis PW 4th. Mathernal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography. J Perinatol 1984; 1: 182-184. Longmire S, Leduc L, Jones MM, et al. The emodinamic effects of intubation during nitroglycerin infusion in severe preclampsia. J Obstet Gynecol 1991; 164: 551-556. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12: 241-247. Losasso TJ, Muzzi DA, Cucchiara RF. Response of fetal heart rate to maternal administration of esmolol. Anesthesiology 1991; 74: 782-784. Loughnan PM, Gold H, Vance JC. Phenytoin teratogenicity in man. Lancet 1973; 1: 70-72. Louik C, Mitchell AA, Prenatal prescription of Macrolide Antibiotics and Infantile Hypertrophic Pyloric Stenosis. Obstetrics and Gynecology 2003; 101; 4: Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. J Obstet Gynecol 2002; 187: 821-822.
Icio facebook furl google newsvine reddit spurl yahoo print single page view reprints reader feedback text size: a controversial drug that can prevent prostate cancer appears to be even more beneficial than previously thought, for example, indomethacin tablets.
Herbal treatments are only part of the solution to not enough milk see protocol to increase breastmilk intake by the baby and ismo.
Blood 1 ml ; was collected by cardiac puncture in heparinized tubes for TxB2 analysis from animals treated i.p. with indomethacin 0.3 mg kg ; or saline three times at 24-h intervals. To determine the extent to which indomethacin inhibited COX activity in vivo, TxB2 a subproduct of TxA2 ; was measured from whole blood platelets after stimulation with a calcium ionophore A23187 ; as previously described 28.
64. Pouraboli I., Hajizaheh S., Najifipour H., Khoshbaten A. 2004 ; . The role of indomethacin and theophylline on knee joint diameter and vascular responses. Kowsar Medical Journal 9 2 ; 101-110. Persian ; 65. Pourheydari, GH., Khodaee, N., Shahriari, A., Sahraee, H., Noroozzadeh, A., Saberi, M., Pirzad Jahromi, J., Khoshbaten A. 2004 ; . Evaluation of the changes in contractility of chick biventer cervices nerve muscle encountered with Paraoxon and Pralidoxime: Introduction of a non-enzematic method. Journal of Military Medicine, 6 1 ; 1-6. Persian ; . 66. B. Rasoulian, M. Jafari, A. Noroozzadeh, H. Mehrani, H. Vahab Aqaee, SMH. Hashemi Madani, A. Asgari, A. Khoshbaten. 2007 ; Effects of IschemiaReperfusion on Rat Renal Tissue Antioxidant Systems and Lipid Peroxidation. J Acta Iranian Medica. in press ; . 67. B. Rasoulian, H. Mohammadhosseniakbari, M. Mofid, G. Baqeri, A. Asgari, A. Ghasemi, MR Bigdeli, HA. Mohebbi, M. Kadkhodaee, A. Khoshbaten, 2007 ; . Preconditioning with intermittent hyperoxia attenuates ischemia-reperfusion injury of the rat kidney. Eur. J. Vascular Surgery. In press ; . 68. Riyahi S., Mofid M., Eimani H., Asgari A., Ghoshooni H., Habibi M., Khoshbaten A. 2006 ; Histological study of topical application of sodium phenytoin 1% ointment on open skin healing in male rats. Iranian J. of Anatomy. 3 4 ; 271-281.